NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analyst consensus: Twelve analysts rate NewAmsterdam Pharma a "Moderate Buy" (1 sell, 1 hold, 9 buy, 1 strong buy) with an average 12‑month price target of $48.00.
• Significant insider selling: CEO Michael H. Davidson sold 443,707 shares (~$14.75M) and a director sold 44,619 shares, with insiders disposing of 1,313,286 shares worth about $42.96M over the last quarter; insiders now own 20.84% of the stock.
• Weak quarterly results and market reaction: The company missed estimates (EPS $(0.63) vs $(0.40) expected, revenue $0.19M vs $0.92M) and reported a deeply negative net margin, while the stock opened at $34.44 (down ~5%), market cap ≈ $3.96B, 1‑year range $15.70–$42.00.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twelve analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $48.00.

NAMS has been the topic of several recent research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. Truist Financial initiated coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, March 18th. They issued a "buy" rating and a $57.00 price target on the stock. Needham & Company LLC lifted their price target on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a "buy" rating in a research note on Wednesday, February 18th. Leerink Partners reiterated an "outperform" rating and issued a $55.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. Finally, HC Wainwright upgraded shares of NewAmsterdam Pharma to a "strong-buy" rating in a research note on Thursday, February 19th.

Insider Activity

In other news, CEO Michael H. Davidson sold 443,707 shares of the business's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the transaction, the chief executive officer directly owned 174,144 shares in the company, valued at $5,790,288. The trade was a 71.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Louis G. Lange sold 44,619 shares of the business's stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $30.42, for a total transaction of $1,357,309.98. Following the transaction, the director owned 10,360 shares in the company, valued at $315,151.20. This represents a 81.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,313,286 shares of company stock valued at $42,963,764 over the last quarter. 20.84% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of NAMS. Frazier Life Sciences Management L.P. grew its stake in NewAmsterdam Pharma by 1.4% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 16,943,774 shares of the company's stock valued at $594,388,000 after buying an additional 241,818 shares during the last quarter. Capital World Investors grew its stake in NewAmsterdam Pharma by 1.6% in the 4th quarter. Capital World Investors now owns 9,984,000 shares of the company's stock valued at $350,239,000 after buying an additional 161,289 shares during the last quarter. Jennison Associates LLC grew its stake in NewAmsterdam Pharma by 42.5% in the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company's stock valued at $119,407,000 after buying an additional 1,252,451 shares during the last quarter. Wellington Management Group LLP grew its stake in NewAmsterdam Pharma by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company's stock valued at $114,332,000 after buying an additional 697,129 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its stake in NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company's stock valued at $54,566,000 after buying an additional 1,062,359 shares during the last quarter. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Trading Down 5.0%

Shares of NAMS stock opened at $34.44 on Wednesday. NewAmsterdam Pharma has a 1 year low of $15.70 and a 1 year high of $42.00. The firm's fifty day moving average price is $32.72 and its two-hundred day moving average price is $34.45. The firm has a market capitalization of $3.96 billion, a P/E ratio of -19.91 and a beta of 0.13.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The business had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.92 million. As a group, equities research analysts forecast that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.